Article
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
British journal of haematology - 1 Oct 2020
Bataller Alex, Oñate Guadalupe, Diaz-Beyá Marina, Guijarro Francesca, Garrido Ana, Vives Susana, Tormo Mar, Arnan Montserrat, Salamero Olga, Sampol Antònia, Coll Rosa, Vall-Llovera Ferran, Oliver-Caldés Aina, López-Guerra Mònica, Pratcorona Marta, Zamora Lurdes, Villamon Eva, Roué Gaël, Blanco Adoración, Nomdedeu Josep F, Colomer Dolors, Brunet Salut, Sierra Jorge, Esteve Jordi
Abstract excerpt
In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.